Farnesyltransferase inhibitors as anticancer agents: Current status

Kuichun Zhu, Andrew Hamilton, Saïd M. Sebti

Research output: Contribution to journalArticle

Abstract

Farnesyltransferase (FTase) is a major molecular target for the development of novel anticancer drugs that are designed to disrupt the aberrant signal transduction circuitry of tumor cells. The discovery more than a decade ago that farnesylation of Ras, one of the most prevalent oncoproteins in human cancers, is required for its cancer-causing activity was the initial stimulus to target FTase. However, it is now clear that yet to be identified farnesylated proteins other than Ras also play a pivotal role as targets for FTase inhibitors (FTIs). In this review, important mechanistic issues on the antiproliferative, pro-apoptotic and anti-angiogenic activities of FTIs, with an emphasis on potential FTI targets, will be discussed. Important clinical issues associated with translational aspects of hypotheses-driven clinical trials will also be discussed.

Original languageEnglish (US)
Pages (from-to)1428-1435
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number12
StatePublished - Dec 2003

Fingerprint

Farnesyltranstransferase
Antineoplastic Agents
Prenylation
ras Proteins
Neoplasms
Oncogene Proteins
Signal Transduction
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Farnesyltransferase
  • Farnesyltransferase inhibitor
  • Prenylation
  • Ras
  • RhoB

ASJC Scopus subject areas

  • Pharmacology

Cite this

Farnesyltransferase inhibitors as anticancer agents : Current status. / Zhu, Kuichun; Hamilton, Andrew; Sebti, Saïd M.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 12, 12.2003, p. 1428-1435.

Research output: Contribution to journalArticle

@article{120afa76f9de49bd9934af2f190ab9b6,
title = "Farnesyltransferase inhibitors as anticancer agents: Current status",
abstract = "Farnesyltransferase (FTase) is a major molecular target for the development of novel anticancer drugs that are designed to disrupt the aberrant signal transduction circuitry of tumor cells. The discovery more than a decade ago that farnesylation of Ras, one of the most prevalent oncoproteins in human cancers, is required for its cancer-causing activity was the initial stimulus to target FTase. However, it is now clear that yet to be identified farnesylated proteins other than Ras also play a pivotal role as targets for FTase inhibitors (FTIs). In this review, important mechanistic issues on the antiproliferative, pro-apoptotic and anti-angiogenic activities of FTIs, with an emphasis on potential FTI targets, will be discussed. Important clinical issues associated with translational aspects of hypotheses-driven clinical trials will also be discussed.",
keywords = "Farnesyltransferase, Farnesyltransferase inhibitor, Prenylation, Ras, RhoB",
author = "Kuichun Zhu and Andrew Hamilton and Sebti, {Sa{\"i}d M.}",
year = "2003",
month = "12",
language = "English (US)",
volume = "4",
pages = "1428--1435",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Farnesyltransferase inhibitors as anticancer agents

T2 - Current status

AU - Zhu, Kuichun

AU - Hamilton, Andrew

AU - Sebti, Saïd M.

PY - 2003/12

Y1 - 2003/12

N2 - Farnesyltransferase (FTase) is a major molecular target for the development of novel anticancer drugs that are designed to disrupt the aberrant signal transduction circuitry of tumor cells. The discovery more than a decade ago that farnesylation of Ras, one of the most prevalent oncoproteins in human cancers, is required for its cancer-causing activity was the initial stimulus to target FTase. However, it is now clear that yet to be identified farnesylated proteins other than Ras also play a pivotal role as targets for FTase inhibitors (FTIs). In this review, important mechanistic issues on the antiproliferative, pro-apoptotic and anti-angiogenic activities of FTIs, with an emphasis on potential FTI targets, will be discussed. Important clinical issues associated with translational aspects of hypotheses-driven clinical trials will also be discussed.

AB - Farnesyltransferase (FTase) is a major molecular target for the development of novel anticancer drugs that are designed to disrupt the aberrant signal transduction circuitry of tumor cells. The discovery more than a decade ago that farnesylation of Ras, one of the most prevalent oncoproteins in human cancers, is required for its cancer-causing activity was the initial stimulus to target FTase. However, it is now clear that yet to be identified farnesylated proteins other than Ras also play a pivotal role as targets for FTase inhibitors (FTIs). In this review, important mechanistic issues on the antiproliferative, pro-apoptotic and anti-angiogenic activities of FTIs, with an emphasis on potential FTI targets, will be discussed. Important clinical issues associated with translational aspects of hypotheses-driven clinical trials will also be discussed.

KW - Farnesyltransferase

KW - Farnesyltransferase inhibitor

KW - Prenylation

KW - Ras

KW - RhoB

UR - http://www.scopus.com/inward/record.url?scp=1642477902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642477902&partnerID=8YFLogxK

M3 - Article

C2 - 14763128

AN - SCOPUS:1642477902

VL - 4

SP - 1428

EP - 1435

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 12

ER -